ReviewDiabetes technology & therapeutics2017
Role of Continuous Glucose Monitoring in Clinical Trials: Recommendations on Reporting.
Review in Diabetes technology & therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 54 citations in OpenAlex.
- Trial
- Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin-treated adults with type 2 diabetes and risk factors for hypoglycaemia.Diabetes, obesity & metabolism · 2021Trial
- Cost-effectiveness of Continuous Glucose Monitoring for Adults With Type 1 Diabetes Compared With Self-Monitoring of Blood Glucose: The DIAMOND Randomized Trial.Diabetes care · 2018Trial
- The Evolving Landscape of Continuous Glucose Monitoring Metrics in Type 1 Diabetes: Narrative Literature Review.JMIR diabetes · 2026Review
- Time-divided hypoglycemia management derived by continuous glucose monitoring may reduce microvascular diseases in type 2 diabetes patients.Endocrine · 2025Article
- Switch from premixed insulin analogue to degludec-liraglutide combination: a CGM study.Frontiers in endocrinology · 2025Article
- Glycaemia in low-premixed insulin analogue type 2 diabetes patients in a real-world setting: are the CGM targets met?European journal of medical research · 2023Observational
- Investigating the value of glucodensity analysis of continuous glucose monitoring data in type 1 diabetes: an exploratory analysis.Frontiers in clinical diabetes and healthcare · 2023Article
- Glycaemic variability in patients with type 2 diabetes mellitus treated with dulaglutide, with and without concomitant insulin: Post hoc analyses of randomized clinical trials.Diabetes, obesity & metabolism · 2022Article
- Stratification of Patients with Diabetes Using Continuous Glucose Monitoring Profiles and Machine Learning.Health data science · 2022Article
- Intermittent Use of Continuous Glucose Monitoring: Expanding the Clinical Value of CGM.Journal of diabetes science and technology · 2021Article
- Continuous Glucose Monitoring Use in Clinical Trials for On-Market Diabetes Drugs.Clinical diabetes : a publication of the American Diabetes Association · 2021Article
- Medical Food Assessment Using a Smartphone App With Continuous Glucose Monitoring Sensors: Proof-of-Concept Study.JMIR formative research · 2021Article
- Individualizing Time-in-Range Goals in Management of Diabetes Mellitus and Role of Insulin: Clinical Insights From a Multinational Panel.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2021Review
- Review
- Fit-for-Purpose Biometric Monitoring Technologies: Leveraging the Laboratory Biomarker Experience.Clinical and translational science · 2021Review
- Flash Continuous Glucose Monitoring in Primary Care Settings: The Need for Measurement of Novel Glycemic Metrics to Adopt Policy and Practice Change.Journal of managed care & specialty pharmacy · 2020Article
- GLU: a software package for analysing continuously measured glucose levels in epidemiology.International journal of epidemiology · 2020Article
- Redefining Hypoglycemia in Clinical Trials: Validation of Definitions Recently Adopted by the American Diabetes Association/European Association for the Study of Diabetes.Diabetes care · 2020Article
- Reporting of hypoglycaemia in clinical trials of basal insulins: A need for consensus.Diabetes, obesity & metabolism · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 9 institutions in 7 countries.
Funding
Abstract
Thanks to significant improvements in the precision, accuracy, and usability of continuous glucose monitoring (CGM), its relevance in both ambulatory diabetes care and clinical research is increasing. In this study, we address the latter perspective and derive provisional reporting recommendations. CGM systems have been available since around the year 2000 and used primarily in people with type 1 diabetes. In contrast to self-measured glucose, CGM can provide continuous real-time measurement of glucose levels, alerts for hypoglycemia and hyperglycemia, and a detailed assessment of glycemic variability. Through a broad spectrum of derived glucose data, CGM should be a useful tool for clinical evaluation of new glucose-lowering medications and strategies. It is the only technology that can measure hyperglycemic and hypoglycemic exposure in ambulatory care, or provide data for comprehensive assessment of glucose variability. Other advantages of current CGM systems include the opportunity for improved self-management of glycemic control, with particular relevance to those at higher risk of or from hypoglycemia. We therefore summarize the current status and limitations of CGM from the perspective of clinical trials and derive suggested recommendations for how these should facilitate optimal CGM use and reporting of data in clinical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.